# Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

> **NCT03592082** · PHASE4 · WITHDRAWN · sponsor: **Bassett Healthcare**

## Conditions studied

- Clostridium Difficile Infection

## Interventions

- **DRUG:** Bismuth Subsalicylate
- **DRUG:** standard antibiotic therapy

## Key facts

- **NCT ID:** NCT03592082
- **Lead sponsor:** Bassett Healthcare
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-01
- **Primary completion:** 2018-07-01
- **Final completion:** 2018-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator left institution
- **Last updated:** 2018-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03592082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03592082, "Use of Bismuth Subsalicylate in Clostridium Difficile Colitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03592082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*